307 related articles for article (PubMed ID: 28661915)
1. Endocrine dysfunction following immune checkpoint inhibitor therapy.
Konda B; Nabhan F; Shah MH
Curr Opin Endocrinol Diabetes Obes; 2017 Oct; 24(5):337-347. PubMed ID: 28661915
[TBL] [Abstract][Full Text] [Related]
2. Endocrine side effects induced by immune checkpoint inhibitors.
Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.
González-Rodríguez E; Rodríguez-Abreu D;
Oncologist; 2016 Jul; 21(7):804-16. PubMed ID: 27306911
[TBL] [Abstract][Full Text] [Related]
4. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.
Chang LS; Barroso-Sousa R; Tolaney SM; Hodi FS; Kaiser UB; Min L
Endocr Rev; 2019 Feb; 40(1):17-65. PubMed ID: 30184160
[TBL] [Abstract][Full Text] [Related]
5. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
Scott ES; Long GV; Guminski A; Clifton-Bligh RJ; Menzies AM; Tsang VH
Eur J Endocrinol; 2018 Feb; 178(2):173-180. PubMed ID: 29187509
[TBL] [Abstract][Full Text] [Related]
6. Thyroid disorders induced by checkpoint inhibitors.
Ferrari SM; Fallahi P; Galetta F; Citi E; Benvenga S; Antonelli A
Rev Endocr Metab Disord; 2018 Dec; 19(4):325-333. PubMed ID: 30242549
[TBL] [Abstract][Full Text] [Related]
7. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
8. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Barroso-Sousa R; Barry WT; Garrido-Castro AC; Hodi FS; Min L; Krop IE; Tolaney SM
JAMA Oncol; 2018 Feb; 4(2):173-182. PubMed ID: 28973656
[TBL] [Abstract][Full Text] [Related]
9. Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.
Braschi-Amirfarzan M; Tirumani SH; Hodi FS; Nishino M
Korean J Radiol; 2017; 18(1):42-53. PubMed ID: 28096717
[TBL] [Abstract][Full Text] [Related]
10. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma.
Kassi E; Angelousi A; Asonitis N; Diamantopoulos P; Anastasopoulou A; Papaxoinis G; Kokkinos M; Giovanopoulos I; Kyriakakis G; Petychaki F; Savelli A; Benopoulou O; Gogas H
Cancer Med; 2019 Nov; 8(15):6585-6594. PubMed ID: 31518074
[TBL] [Abstract][Full Text] [Related]
11. Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers.
Sood A; Cole D; Abdollah F; Eilender B; Roumayah Z; Deebajah M; Dabaja A; Alanee S
Curr Urol Rep; 2018 Jul; 19(9):68. PubMed ID: 29971696
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies.
Ferrari SM; Fallahi P; Elia G; Ragusa F; Ruffilli I; Patrizio A; Galdiero MR; Baldini E; Ulisse S; Marone G; Antonelli A
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137683
[TBL] [Abstract][Full Text] [Related]
13. Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.
Park JA; Cheung NV
Cancer Treat Rev; 2017 Jul; 58():22-33. PubMed ID: 28622628
[TBL] [Abstract][Full Text] [Related]
14. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.
Byun DJ; Wolchok JD; Rosenberg LM; Girotra M
Nat Rev Endocrinol; 2017 Apr; 13(4):195-207. PubMed ID: 28106152
[TBL] [Abstract][Full Text] [Related]
15. Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists.
Illouz F; Briet C; Cloix L; Le Corre Y; Baize N; Urban T; Martin L; Rodien P
Cancer Med; 2017 Aug; 6(8):1923-1929. PubMed ID: 28719055
[TBL] [Abstract][Full Text] [Related]
16. Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces.
Deligiorgi MV; Liapi C; Trafalis DT
Expert Opin Biol Ther; 2021 Aug; 21(8):1097-1120. PubMed ID: 33393372
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.
Kanie K; Iguchi G; Bando H; Urai S; Shichi H; Fujita Y; Matsumoto R; Suda K; Yamamoto M; Fukuoka H; Ogawa W; Takahashi Y
Cancer Immunol Immunother; 2021 Dec; 70(12):3669-3677. PubMed ID: 33977343
[TBL] [Abstract][Full Text] [Related]
18. Endocrine sequelae of immune checkpoint inhibitors.
Ntali G; Kassi E; Alevizaki M
Hormones (Athens); 2017 Oct; 16(4):341-350. PubMed ID: 29518754
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy-associated hypophysitis.
Solinas C; Porcu M; De Silva P; Musi M; Aspeslagh S; Scartozzi M; Willard-Gallo K; Mariotti S; Saba L
Semin Oncol; 2018 Jun; 45(3):181-186. PubMed ID: 30352754
[TBL] [Abstract][Full Text] [Related]
20. [Endocrinopathies Associated with Immune Checkpoint Inhibitors].
Santos MJ
Acta Med Port; 2022 Mar; 35(3):209-215. PubMed ID: 35077347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
